Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33


ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases.

Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders CK, Carrillo JA, Chalasani P, Kabos P, Puhalla SL, Tkaczuk KHR, Garcia A, Ahluwalia MS, Wefel JS, Lakhani N, Ibrahim NK.

Clin Cancer Res. 2020 Jan 22. pii: clincanres.3258.2019. doi: 10.1158/1078-0432.CCR-19-3258. [Epub ahead of print]


Association of Serum Progranulin Levels With Disease Progression, Therapy Response and Survival in Patients With Metastatic Breast Cancer.

Tkaczuk KHR, Hawkins D, Yue B, Hicks D, Tait N, Serrero G.

Clin Breast Cancer. 2019 Dec 5. pii: S1526-8209(19)30758-X. doi: 10.1016/j.clbc.2019.11.010. [Epub ahead of print]


Trends in utilization of hypofractionated whole breast irradiation (HF-WBI) in triple negative breast cancer (TNBC): a national cancer database (NCDB) analysis.

Rice SR, Feigenberg SJ, Hamza M, Molitoris JK, Bentzen SM, Tkaczuk KHR, Rosenblatt PM, Bellavance EC, Nichols EM.

Breast Cancer Res Treat. 2019 Jun;175(2):473-478. doi: 10.1007/s10549-019-05150-x. Epub 2019 Feb 22.


Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.

Blackwell KL, Zaman K, Qin S, Tkaczuk KHR, Campone M, Hunt D, Bryce R, Goldstein LJ; 202 Study Group.

Clin Breast Cancer. 2019 Apr;19(2):97-104.e4. doi: 10.1016/j.clbc.2018.12.011. Epub 2018 Dec 20.


Enhanced cancer therapy with cold-controlled drug release and photothermal warming enabled by one nanoplatform.

Wang H, Agarwal P, Liang Y, Xu J, Zhao G, Tkaczuk KHR, Lu X, He X.

Biomaterials. 2018 Oct;180:265-278. doi: 10.1016/j.biomaterials.2018.07.021. Epub 2018 Jul 17.


Prevalence and risk of skeletal complications and use of radiation therapy in elderly women diagnosed with metastatic breast cancer.

Hussain A, Yong C, Tkaczuk KHR, Qian Y, Arellano J, Mullins CD, Onukwugha E.

PLoS One. 2018 Mar 1;13(3):e0193661. doi: 10.1371/journal.pone.0193661. eCollection 2018.


Factors Influencing Management and Outcome in Patients with Occult Breast Cancer with Axillary Lymph Node Involvement: Analysis of the National Cancer Database.

Hessler LK, Molitoris JK, Rosenblatt PY, Bellavance EC, Nichols EM, Tkaczuk KHR, Feigenberg SJ, Bentzen SM, Kesmodel SB.

Ann Surg Oncol. 2017 Oct;24(10):2907-2914. doi: 10.1245/s10434-017-5928-x. Epub 2017 Aug 1.


Utilization of hypofractionated whole-breast radiation therapy in patients receiving chemotherapy: a National Cancer Database analysis.

Diwanji TP, Molitoris JK, Chhabra AM, Snider JW, Bentzen SM, Tkaczuk KH, Rosenblatt PY, Kesmodel SB, Bellavance EC, Cohen RJ, Cheston SB, Nichols EM, Feigenberg SJ.

Breast Cancer Res Treat. 2017 Sep;165(2):445-453. doi: 10.1007/s10549-017-4345-y. Epub 2017 Jun 21.


Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors.

Kesmodel SB, Goloubeva OG, Rosenblatt PY, Heiss B, Bellavance EC, Chumsri S, Bao T, Thompson J, Nightingale G, Tait NS, Nichols EM, Feigenberg SJ, Tkaczuk KH.

Am J Clin Oncol. 2018 May;41(5):508-512. doi: 10.1097/COC.0000000000000314.


Weight loss with mindful eating in African American women following treatment for breast cancer: a longitudinal study.

Chung S, Zhu S, Friedmann E, Kelleher C, Kozlovsky A, Macfarlane KW, Tkaczuk KH, Ryan AS, Griffith KA.

Support Care Cancer. 2016 Apr;24(4):1875-81. doi: 10.1007/s00520-015-2984-2. Epub 2015 Oct 13.


Breast magnetic resonance imaging (MRI) surveillance in breast cancer survivors.

Weinstock C, Campassi C, Goloubeva O, Wooten K, Kesmodel S, Bellevance E, Feigenberg S, Ioffe O, Tkaczuk KH.

Springerplus. 2015 Aug 28;4:459. doi: 10.1186/s40064-015-1158-5. eCollection 2015.


Trastuzumab-induced cardiomyopathy: incidence and associated risk factors in an inner-city population.

Baron KB, Brown JR, Heiss BL, Marshall J, Tait N, Tkaczuk KH, Gottlieb SS.

J Card Fail. 2014 Aug;20(8):555-9. doi: 10.1016/j.cardfail.2014.05.012. Epub 2014 Jun 4.


Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms.

Bao T, Cai L, Snyder C, Betts K, Tarpinian K, Gould J, Jeter S, Medeiros M, Chumsri S, Bardia A, Tan M, Singh H, Tkaczuk KH, Stearns V.

Cancer. 2014 Feb 1;120(3):381-9. doi: 10.1002/cncr.28352. Epub 2013 Dec 23.


Stereotactic Ablative Radiotherapy (SABR): Impact on the Immune System and Potential for Future Therapeutic Modulation.

Reese AS, Feigenberg SJ, Husain A, Webb TJ, Hausner PF, Edelman MJ, Feliciano J, Tkaczuk KH, Sharma NK.

Mol Cell Pharmacol. 2013 Jan 1;5(1):19-25.


Update on taxane development: new analogs and new formulations.

Yared JA, Tkaczuk KH.

Drug Des Devel Ther. 2012;6:371-84. doi: 10.2147/DDDT.S28997. Epub 2012 Dec 11. Review.


A culturally specific dietary plan to manage weight gain among African American breast cancer survivors: a feasibility study.

Griffith KA, Royak-Schaler R, Nesbitt K, Zhan M, Kozlovsky A, Hurley K, Pelser C, Tkaczuk KH, Ryan AS.

Nutr Health. 2012 Apr;21(2):97-105. doi: 10.1177/0260106012459938. Epub 2012 Nov 7.


Increasing national mastectomy rates for the treatment of early stage breast cancer.

Mahmood U, Hanlon AL, Koshy M, Buras R, Chumsri S, Tkaczuk KH, Cheston SB, Regine WF, Feigenberg SJ.

Ann Surg Oncol. 2013 May;20(5):1436-43. doi: 10.1245/s10434-012-2732-5. Epub 2012 Nov 8.


Computer assisted quantitative immunofluorescence of tumor tissue marker expression and clinical outcome to chemotherapy in advanced breast cancer patients.

Tkaczuk KH, Tait NS, Ioffe O, Tan M, Goloubeva OG, Lesko SA, Deamond SF, Zhou D, Lum ZP, Sutula MJ, Van Echo D, Ts'o PO.

Discov Med. 2011 Jul;12(62):33-40.


Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.

Tkaczuk KH.

Clin Ther. 2009;31 Pt 2:2273-89. doi: 10.1016/j.clinthera.2009.11.011. Review.


Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells.

Burks SR, Macedo LF, Barth ED, Tkaczuk KH, Martin SS, Rosen GM, Halpern HJ, Brodie AM, Kao JP.

Breast Cancer Res Treat. 2010 Nov;124(1):121-31. doi: 10.1007/s10549-009-0715-4. Epub 2010 Jan 12.


Evidence-based care for breast cancer survivors: communicating the Institute of Medicine Guidelines in medical practice.

Royak-Schaler R, Gardner LD, Shardell M, Zhan M, Passmore SR, Gadalla SM, Hoy MK, Tkaczuk KH, Nesbitt K.

Patient Educ Couns. 2009 Dec;77(3):413-20. doi: 10.1016/j.pec.2009.09.042. Epub 2009 Nov 2.


The significance of circulating epithelial cells in Breast Cancer patients by a novel negative selection method.

Tkaczuk KH, Goloubeva O, Tait NS, Feldman F, Tan M, Lum ZP, Lesko SA, Van Echo DA, Ts'o PO.

Breast Cancer Res Treat. 2008 Sep;111(2):355-64. Epub 2007 Dec 7.


Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L.

J Clin Oncol. 2003 Mar 15;21(6):976-83.


Can obesity explain the racial difference in stage of breast cancer at diagnosis between black and white women?

Cui Y, Whiteman MK, Langenberg P, Sexton M, Tkaczuk KH, Flaws JA, Bush TL.

J Womens Health Gend Based Med. 2002 Jul-Aug;11(6):527-36.


Body mass and stage of breast cancer at diagnosis.

Cui Y, Whiteman MK, Flaws JA, Langenberg P, Tkaczuk KH, Bush TL.

Int J Cancer. 2002 Mar 10;98(2):279-83.


Social support as a buffer to the psychological impact of stressful life events in women with breast cancer.

Kornblith AB, Herndon JE 2nd, Zuckerman E, Viscoli CM, Horwitz RI, Cooper MR, Harris L, Tkaczuk KH, Perry MC, Budman D, Norton LC, Holland J; Cancer and Leukemia Group B.

Cancer. 2001 Jan 15;91(2):443-54.


Phase I study of docetaxel and topotecan in patients with solid tumors.

Tkaczuk KH, Zamboni WC, Tait NS, Meisenberg BR, Doyle LA, Edelman MJ, Hausner PF, Egorin MJ, Van Echo DA.

Cancer Chemother Pharmacol. 2000;46(6):442-8.


A phase I study of paclitaxel, UFT, and leucovorin.

Gojo I, Tkaczuk KH.

Oncology (Williston Park). 2000 Oct;14(10 Suppl 9):76-8.


Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors.

Zamboni WC, Egorin MJ, Van Echo DA, Day RS, Meisenberg BR, Brooks SE, Doyle LA, Nemieboka NN, Dobson JM, Tait NS, Tkaczuk KH.

J Clin Oncol. 2000 Sep 15;18(18):3288-94.


Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.

Eisenberger MA, Sinibaldi VJ, Reyno LM, Sridhara R, Jodrell DI, Zuhowski EG, Tkaczuk KH, Lowitt MH, Hemady RK, Jacobs SC, et al.

J Clin Oncol. 1995 Sep;13(9):2174-86.


Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.

Jodrell DI, Reyno LM, Sridhara R, Eisenberger MA, Tkaczuk KH, Zuhowski EG, Sinibaldi VJ, Novak MJ, Egorin MJ.

J Clin Oncol. 1994 Jan;12(1):166-75.


Suramin, an active drug for prostate cancer: interim observations in a phase I trial.

Eisenberger MA, Reyno LM, Jodrell DI, Sinibaldi VJ, Tkaczuk KH, Sridhara R, Zuhowski EG, Lowitt MH, Jacobs SC, Egorin MJ.

J Natl Cancer Inst. 1993 Apr 21;85(8):611-21. Erratum in: J Natl Cancer Inst 1994 Apr 20;86(8):639-40.


Supplemental Content

Loading ...
Support Center